

80 Robinson Road #02-00 Singapore 068898 Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

## FOR IMMEDIATE RELEASE

# QT Vascular's Key Technologies Featured In Major International Conferences

- China Endovascular Course (CEC) and Innovations Cardiovascular Interventions (ICI) attended by vascular interventional experts from around the world
- Increasing recognition and adoption of QT Vascular's technologies from thoughtleaders and distribution partners

**Singapore, 17 December 2014** – Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that several of its key technologies were recently featured in the scientific programs at two major international meetings, the China Endovascular Course (CEC) in Beijing and the Innovations in Cardiovascular Interventions (ICI) conference in Tel Aviv.

Speaking on behalf of the Group at CEC on 29 November 2014, Mr. Christopher Haig, Vice President of Corporate Development, delivered three presentations titled *Overview of a New PTA Balloon:* GliderXtreme<sup>TM</sup>, A New Treatment Paradigm for Peripheral Disease: The Chocolate® PTA Balloon and View to the Future: Drug-Coated Chocolate® Touch. These presentations were closely followed on 15 December 2014, where Dr. Michael Jaff of Massachusetts General Hospital spoke in a highly attended session at ICI on The Chocolate® Balloon: Does This Redefine Peripheral PTA?

"The unique clinical value of our technology is being proven through clinical studies and increased market adoption," commented Dr. Eitan Konstantino, the Group's Chief Executive Officer. "Whether it is through our partnership with WEGO\* in China or through collaboration with eminent physicians such as Dr. Jaff, the Group's products are receiving increasing recognition from thought leaders around the world."

Notes:

\* Weihai Weigao Medical Devices, Ltd.


-End-

## **About Peripheral Arterial Disease**

Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide <sup>(1)</sup>.

# **About Coronary Artery Disease**

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.



80 Robinson Road #02-00 Singapore 068898 Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

### About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

For more information, please refer to: http://www.gtvascular.com/

(1) "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.

Issued for and on behalf of QT Vascular Ltd. by Financial PR Pte Ltd

Kamal SAMUEL, <u>kamal@financialpr.com.sg</u> Mark LIN, <u>marklin@financialpr.com.sg</u> Tel: (65) 6438 2990 Fax: (65) 6438 0064

### Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.